Cheap as chips, page-91

So we're expecting some 'top line' data re BTX1308 (Psoriasis) hopefully early Q2.........so April perhaps........what I find very compelling about all of BOT's products is their high possibility for 'success via overlap'.........i.e if one is proven successful then there's a very good probability that the others will prove out in addition............

"Atopic dermatitis (and psoriasis) are both T-cell mediated inflammatory diseases of the skin"..........and our AT data for phase 1 looked great.............

"BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of AD1".......etc etc.

There is a significant demonstrated antimicrobial effect also........

And we have this to consider also......."worldwide Botanix holds the exclusive rights to utilise Permetrex^TM for all drugs that treat skin diseases"...........lower dose levels leads to better safety profiles/extended use scenarios and so on.